Y 9000
Y 9000 is an orally active antiallergic and anti-inflammatory compound. Y 9000 targets mast cells, inhibits the release of allergic mediators, stimulates the adrenal glands, exhibits glucocorticoid-like activity, and reduces adrenal ascorbic acid content. Y 9000 inhibits IgE-mediated and IgG-mediated allergic reactions as well as active systemic anaphylaxis in mice. Y 9000 inhibits allergic wheezing in passively sensitized guinea pigs and protects against active systemic anaphylactic shock in mice. Y 9000 inhibits non-immune responses in rats, including dextran-induced histamine release, anaphylactoid reactions and paw swelling. Y 9000 can be used in the research of allergic diseases (asthma, allergic rhinitis, urticaria, etc.).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 53944-40-4
- Formule: C14H9NO3
- Masse moléculaire:239.23
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Y 9000 (50-250 mg/kg; p.o.; single dose 1 hour pre-antigen; 5-100 mg/kg; i.p.; single dose 30 minutes pre-antigen; 25-100 mg/kg; p.o.; single dose 1 hour pre-antigen in adrenalectomized rats) inhibits IgG-mediated 4-hour heterologous PCA in intact rats in a dose-dependent manner, with an oral ED50 of 75 mg/kg and intraperitoneal ED50 of 14 mg/kg, and this inhibitory effect is reduced in adrenalectomized rats[1].
Y 9000 (5-25 mg/kg; i.p.; single dose 30 minutes pre-antigen; 100 mg/kg; p.o.; single dose 2 hours pre-antigen) inhibits IgE-mediated active anaphylactic bronchoconstriction in sensitized rats in a dose-dependent manner via intraperitoneal and oral routes[1].
Y 9000 (25-100 mg/kg; i.p.; single dose 30 minutes pre-aerosol challenge) inhibits IgG-mediated anaphylactic asthma in passively sensitized guinea pigs via intraperitoneal administration, with an ED50 of 50 mg/kg[1].
Y 9000 (100-500 mg/kg; p.o.; single dose 1 hour pre-antigen; 10-100 mg/kg; i.p.; single dose 30 minutes pre-antigen) dose-dependently protects against active systemic anaphylaxis in sensitized mice, with an oral ED50 of ~250 mg/kg and intraperitoneal ED50 of 50 mg/kg[1].
Y 9000 (2.5-25 mg/kg; p.o.; single dose 1 hour pre-induction; 0.5-10 mg/kg; i.p.; single dose 30 minutes pre-induction) inhibits egg albumin-induced anaphylactoid reactions in rats in a dose-dependent manner via oral and intraperitoneal routes, with an oral ED50 of 4 mg/kg and intraperitoneal ED50 of 1 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 180g body weight; male, 200g body weight; allergic reaction model via 48-hour homologous passive cutaneous anaphylaxis induced by anti-egg albumin rat serum or anti-dinitrophenol-ascaris rat serum)[1]
-
Dosage:5-50 mg/kg (p.o.); 0.5-50 mg/kg (i.p.)
-
Administration:p.o.; single dose 1 hour pre-antigen; i.p.; single dose 30 minutes pre-antigen
-
Result:Suppressed egg albumin-triggered PCA dose-dependently via oral and intraperitoneal routes, with oral ED50 of 11 mg/kg and intraperitoneal ED50 of 2.7 mg/kg.
Suppressed DNP-As-induced PCA orally in a serum dilution-dependent fashion, with ED50 values of 30 mg/kg (1:30), 11 mg/kg (1:50) and ~4 mg/kg (1:100).
-
Animal Model:Wistar rats (male, 180g body weight; adrenalectomized male, 180g body weight, 5 days post-surgery; allergic reaction model via 4-hour heterologous passive cutaneous anaphylaxis induced by anti-egg albumin rabbit serum)[1]
-
Dosage:50-250 mg/kg (p.o. intact rats); 5-100 mg/kg (i.p. intact rats); 25-100 mg/kg (p.o. adrenalectomized rats)
-
Administration:p.o.; single dose 1 hour pre-antigen; i.p.; single dose 30 minutes pre-antigen
-
Result:Suppressed IgG-dependent 4 hr heterologous PCA in normal rats dose-dependently, with oral ED50 = 75 mg/kg and intraperitoneal ED50 = 14 mg/kg.
Suppressed IgG-dependent 4 hr heterologous PCA by 26% and 61% at oral 25 mg/kg and 100 mg/kg in adrenalectomized rats.
-
Animal Model:Wistar rats (female, 200g body weight; allergic asthma model via active anaphylactic bronchoconstriction induced by egg albumin and Bordetella pertussis vaccine sensitization)[1]
-
Dosage:5-25 mg/kg (i.p.); 100 mg/kg (p.o.)
-
Administration:i.p.; single dose 30 minutes pre-antigen; p.o.; single dose 2 hours pre-antigen
-
Result:Suppressed antigen-triggered anaphylactic bronchoconstriction dose-dependently via intraperitoneal injection and matched the potency of disodium cromoglycate; oral 100 mg/kg also exerted prominent suppressive effects.
-
Animal Model:Guinea pigs (male, 300-400g body weight; allergic asthma model via anaphylactic asthma induced by passive sensitization with anti-egg albumin rabbit serum and egg albumin aerosol challenge)[1]
-
Dosage:25-100 mg/kg
-
Administration:i.p.; single dose 30 minutes pre-aerosol challenge
-
Result:Protected 0/10, 5/10, 6/10 animals from anaphylactic asthma at intraperitoneal doses of 25 mg/kg, 50 mg/kg, 100 mg/kg respectively, with an ED50 of 50 mg/kg.
-
Animal Model:ICR mice (female, 20-25g body weight; allergic reaction model via active systemic anaphylaxis induced by egg albumin and Bordetella pertussis vaccine sensitization)[1]
-
Dosage:100-500 mg/kg (p.o.); 10-100 mg/kg (i.p.)
-
Administration:p.o.; single dose 1 hour pre-antigen; i.p.; single dose 30 minutes pre-antigen
-
Result:Suppressed lethal active systemic anaphylaxis dose-dependently.
-
Animal Model:Wistar rats (male, 180-200g body weight; anaphylactoid reaction model via egg albumin-induced anaphylactoid reaction)[1]
-
Dosage:2.5-25 mg/kg (p.o.); 0.5-10 mg/kg (i.p.)
-
Administration:p.o.; single dose 1 hour pre-induction; i.p.; single dose 30 minutes pre-induction
-
Result:Suppressed egg albumin-evoked anaphylactoid responses dose-dependently, with oral ED50 of 4 mg/kg and intraperitoneal ED50 of 1 mg/kg; intraperitoneal potency was approximately 3.4-fold higher than disodium cromoglycate.
Chemical Information
-
CAS No. 53944-40-4
-
Masse moléculaire 239.23
-
Formule C14H9NO3
-
SMILES
O=C1C2=CC(C(C)=O)=CC=C2OC3=NC=CC=C31
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Y 9000 Related Classifications
HY-123013 Related Classifications
Powered by Bioz
- Y 9000
- 53944-40-4
- Y9000
- Y-9000
- Biochemical Assay Reagents
- IgG-mediated reactions
- dextran-induced histamine release
- IgE-mediated reactions
- glucocorticoid-like activity
- allergic diseases
- paw edema
- mouse active systemic anaphylactic reactions
- anaphylactoid reaction
- allergic mediators
- adrenals
- Inhibitor
- inhibitor
- inhibit